MBD3 (D1B8F) Rabbit Monoclonal Antibody#99169,Cell Signaling Technology (CST),99169
MBD3 (D1B8F) Rabbit Monoclonal Antibody recognizes endogenous levels of total MBD3 protein.
Host
Rabbit
Reactivity
Human, Mouse, Rat, Monkey
Application
Western Blotting: 1:1000 Chromatin IP: 1:50 Chromatin IP-seq: 1:50 CUT&RUN: 1:50
Platform ID
BAB923947081
.png)
Cell Signaling Technology (CST)
Contact
Tel: 877-616-2355,978-867-2388
Fax: 877-616-2355
Email:
Specifications
Scientific Background
Methyl-CpG-binding protein 2 (MeCP2) is the founding member of a family of methyl-CpG-binding domain (MBD) proteins that also includes MBD1, MBD2, MBD3, MBD4, MBD5, and MBD6 (1-3). Apart from MBD3, these proteins bind methylated cytosine residues in the context of the di-nucleotide 5´-CG-3´ to establish and maintain regions of transcriptionally inactive chromatin by recruiting a variety of co-repressor proteins (2). MeCP2 recruits histone deacetylases HDAC1 and HDAC2, and the DNA methyltransferase DNMT1 (4-6). MBD1 couples transcriptional silencing to DNA replication and interacts with the histone methyltransferases ESET and SUV39H1 (7,8). MBD2 and MBD3 co-purify as part of the NuRD (nucleosome remodeling and histone de-acetylation) co-repressor complex, which contains the chromatin remodeling ATPase Mi-2, HDAC1, and HDAC2 (9,10). MBD5 and MBD6 have recently been identified and little is known regarding their protein interactions. MBD proteins are associated with cancer and other diseases; MBD4 is best characterized for its role in DNA repair and MBD2 has been linked to intestinal cancer (11,12). Mutations in theMeCP2gene cause the neurologic developmental disorder Rett Syndrome (13). MeCP2 protein levels are high in neurons, where it plays a critical role in multiple synaptic processes (14). In response to various physiological stimuli, MeCP2 is phosphorylated on Ser421 and regulates the expression of genes controlling dendritic patterning and spine morphogenesis (14). Disruption of this process in individuals with altered MeCP2 may cause the pathological changes seen in Rett Syndrome.Clouaire, T. and Stancheva, I. (2008)Cell Mol Life Sci65, 1509-22.Hendrich, B. and Bird, A. (1998)Mol Cell Biol18, 6538-47.Roloff, T.C. et al. (2003)BMC Genomics4, 1.Nan, X. et al. (1998)Nature393, 386-9.Jones, P.L. et al. (1998)Nat Genet19, 187-91.Fuks, F. et al. (2003)J Biol Chem278, 4035-40.Sarraf, S.A. and Stancheva, I. (2004)Mol Cell15, 595-605.Fujita, N. et al. (2003)J Biol Chem278, 24132-8.Zhang, Y. et al. (1999)Genes Dev13, 1924-35.Wade, P.A. et al. (1999)Nat Genet23, 62-6.Hendrich, B. et al. (1999)Nature401, 301-4.Sansom, O.J. et al. (2003)Nat Genet34, 145-7.Miltenberger-Miltenyi, G. and Laccone, F. (2003)Hum Mutat22, 107-15.Zhou, Z. et al. (2006)Neuron52, 255-69.Alternate NamesMBD3; methyl-CpG binding domain protein 3; Methyl-CpG-binding domain protein 3; Methyl-CpG-binding protein MBD3
Synonyms
MBD3; methyl-CpG binding domain protein 3; Methyl-CpG-binding domain protein 3; Methyl-CpG-binding protein MBD3
Category Paths
- Products>Trial Size Antibodies
Please provide the required information below so that we can quickly source your products.
